GE HealthCare's Vizamyl Receives FDA Approval for Quantitative Amyloid Detection

GE HealthCare's Vizamyl has received FDA approval for quantitative Alzheimer's amyloid detection, allowing for objective calculation of amyloid load in the brain. The updated label expands the agent's indications, removes prior limitations, and indicates its use for selecting patients eligible for anti-amyloid therapy.